Slide 1: Investor Presentation May 2026
Investor Presentation May 2026
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Senores Pharmaceuticals Limited (the “Company” / “SPL”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscri
Slide 3: Financial & Operational Highlights Q4 & FY26
Financial & Operational Highlights Q4 & FY26 Private & Confidential
Slide 4: Key Highlights FY26
Key Highlights FY26 FINANCIAL HIGHLIGHTS BUSINESS HIGHLIGHTS Strong Improvement in Cash Flow Operations Cash Flow from Operations for FY26 stood at Rs. 75 crs, showing significant Acquisition of Zoraya Pharmaceuticals improvement over last year. EBITDA-to-Operating Cash Flow conversion has Entered i
Slide 5: Regulated Market Owned Product Portfolio & Visibility
Regulated Market Owned Product Portfolio & Visibility Owned ANDA’s Corresponding ANDA Products* Huge Opportunity Q4FY25 Q4FY26 Q4FY25 Q4FY26 Approved ANDAs 26 51 61 151 Scaled up Own ANDAs by 2x and Corresponding ANDA products by 2.5x over the last 12 months Commercialized ANDAs 11 21 22 46 30 ANDAs
Slide 6: CDMO / CMO & Emerging Market Opportunity
CDMO / CMO & Emerging Market Opportunity Products Corresponding ANDA Products* Huge Opportunity Q4FY25 Q4FY26 Q4FY25 Q4FY26 CDMO/CMO business focused on specialty, government supplies CDMO/ CMO and controlled substances. Commercialized Products 13 16 22 34 Uniquely positioned in USA & India to provi
Slide 7: Consolidated Financial Highlights – Q4 & FY26
Consolidated Financial Highlights – Q4 & FY26 Total Income (Rs. Crs)* EBITDA (Rs. Crs) PAT (Rs. Crs) +62% +96% +108% 664.0 199.6 121.5 410.3 58% 144% 101.8 105% 58.3 189.7 61.9 36.7 120.2 17.9 25.4 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Gross Profit Margin (%) EBITDA
Slide 8: Segmental Financial Highlights – Q4 & FY26
Segmental Financial Highlights – Q4 & FY26 Segment Revenue (INR Cr) Q4FY26 Q4FY25 Y-o-Y FY26 FY25 Y-o-Y Regulated Markets 117.8 64.3 83.0% 427.4 244.8 74.6% Emerging Markets 45.9 36.5 25.8% 145.0 121.2 19.7% Branded Generics 9.4 4.0 132.4% 40.0 8.2 385.3% Others Operating 36.2 42.7% 16.6 15.3 8.8% 5
Slide 9: Consolidated Profit & Loss Account – Q4 & FY26
Consolidated Profit & Loss Account – Q4 & FY26 Consolidated P&L (Rs. Crs) Q4 FY26 Q4 FY25 Y-o-Y FY26 FY25 Y-o-Y Revenue from Operations 175.1 108.7 632.6 390.8 Other Operating Income 14.5 11.5 31.3 19.5 Total Income 189.7 120.2 57.8% 664.0 410.3 61.8% Total COGS 66.2 57.5 251.7 180.7 Gross Profit 12
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (INR Crs) Mar-26 Mar-25 EQUITY AND LIABILITIES (INR Crs) Mar-26 Mar-25 Non-Current Assets Equity Property, Plant and Equipment 331.4 198.9 Equity Share Capital 46.1 46.1 Capital Work-in-Progress 17.5 44.2 Other Equity 887.6 740.1 Goodwill 46.5 38.2 Total Shareholder
Slide 11: Consolidated Abridged Cash Flow Statement
Consolidated Abridged Cash Flow Statement Cash Flow Statement (INR Mn) FY26 FY25 Profit/(Loss) Before Tax 159.1 70.6 Adjustments for Non-Cash and Non-Operational Expenses / (Incomes) 58.0 27.1 Operating Profit / (Loss) Before Working Capital Changes 217.1 97.7 Changes in Working Capital -141.9 -134.
Slide 12: Update on Utilization of Funds from IPO
Update on Utilization of Funds from IPO Amount as proposed in the Amount utilized as on Amount Unutilized as on Sr. No. Object as per Offer Document Offer revised Mar 31, 2026 Mar 31, 2026 (Rs. Crs) (Rs. Crs) (Rs. Crs) Investment in one of our Subsidiaries, Havix, to fund capital expenditure 1 requi
Slide 13: Growth Strategies
Growth Strategies Private & Confidential
Slide 14: Key Strategies
Key Strategies Significantly enhance market Inorganic growth through synergistic acquisitions presence in North America & other Regulated Markets Integrated approach by Launch products with the potential enhancing capabilities for of NDA approval in the US backward integration Expanding into new Reg
Slide 15: Enhance Market Presence of Marketed Products in North America
Enhance Market Presence of Marketed Products in North America and Other Regulated Markets US accounts for 43% of the global pharma market, 56% of the regulated market & 91% Persistent drug shortage calls for an of North America Market increased supply of generic drugs Global pharma market by classif
Slide 16: Entering into Strategic Alliance for CMO/CDMO in Regulated Markets
Entering into Strategic Alliance for CMO/CDMO in Regulated Markets CDMO market growing faster than the pharma market Strategic alliance for CMO/CDMO in Regulated Markets which is growing at 7.7% US CDMO/CMO market (USD bn) The dependence on CDMO/CMO’s has increased as they offer 7.7% Appended Manufa
Slide 17: Expanding into New Regulated & Emerging Markets
Expanding into New Regulated & Emerging Markets Regulated & Emerging markets witnessing strong growth Global pharma market by classification (USD bn) Emerging pharma market by Product (2028F) Regulated pharma market by Product (2028F) Regulated Emerging Innovator Generic Generic Innovator 541.0 376.
Slide 18: Enhancing Capabilities for Backward Integration
Enhancing Capabilities for Backward Integration Indian API export market to grow at a CAGR of 8.4% Pursuing an integrated approach for greater backward integration API exports (USD bn) Setup Greenfield unit - Increase API manufacturing capacity CAGR: 8.4% Proposed from 25 MTPA to 169 MTPA 7.1 Expans
Slide 19: About Senores Pharmaceuticals Limited
About Senores Pharmaceuticals Limited Private & Confidential
Slide 20: Introduction to Senores Pharma
Introduction to Senores Pharma Brief Overview Global Research driven Formulation Focused company engaged in developing & At a Glance manufacturing of pharmaceutical products predominantly for the Regulated Markets of the US, Canada & UK across various therapeutic areas Niche Product Identification C
Slide 21: Business Segments
Business Segments 64% 22% 13% FY26 Income Regulated Markets Emerging Markets Others Rs. 664 Crs Regulated Markets Business Emerging Markets Business Develop & manufacture pharmaceutical products for the Primarily serves the US, Canada and United Kingdom Emerging Markets USFDA approved facility in At
Slide 22: Distinct Specialty & Complex Product Portfolio Built in a Short Span
1 Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets Demonstrated Capability to propel Products from Conception to Commercialization Product Identification Product Development Commercial Data Analysis – IQVIA, R&D to establish API Partner Finalization Concurre
Slide 23: Key Strengths of the Company
Key Strengths of the Company 1 Distinct specialty and complex product portfolio built in a short span for Regulated Markets 2 Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets 3 Presence in the Emerging Markets with portfolio, including specialty and complex pro
Slide 24: Key Events & Milestones
Key Events & Milestones Acquired a 51% stake in Zoraya Incorporated a wholly owned Consolidated presence in emerging Pharmaceuticals, LLC (Nov 2025) Incorporated as “Senores subsidiary, Senores Pharmaceuticals markets by acquiring shares in Ratnatris Acquired 75% stake in Apnar Pharmaceuticals Pvt.
Slide 25: Presence in Regulated Markets through Long-term marketing arrangements
2 Presence in Regulated Markets through Long -term marketing arrangements MARKETED PRODUCTS CDMO / CMO Business Model Business Model Identify, Develop & Commercialize specialty & complex Customized formulation, development & manufacturing niche products in mid - market range capabilities for custome
Slide 26: Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products
3 Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products Special Focus Niche & Specialty patented products in the US with early launch 597 opportunity in Emerging Markets 40+ 113 South East Asia Countries Commonwealth of Sugammadex Ferric Marketed Independent States
Slide 27: Corporate Structure
Corporate Structure Group holding company based in India Houses Domestic Branded Generics business & API business Senores Pharmaceuticals Inc. Senores Pharmaceuticals Inc. Ratnatris Pharmaceuticals Pvt Ltd. Enters U.S. Federal Market Apnar Pharma Pvt. Ltd.- Marketing cum ANDA Marketing cum ANDA Cate
Slide 28: Professional and Dedicated Management Team (1/2)
6 Professional and Dedicated Management Team (1/2) Sanjay Shaileshbhai Majmudar Swapnil Jatinbhai Shah Deval Rajnikant Shah Chairman & Non-Executive, Promoter & Managing Director Whole-Time Director & CFO Non- Independent Director ▪ 17+ years of experience in the pharma sector ▪ 40+ years of experie
Slide 29: Professional and Dedicated Management Team (2/2)
6 Professional and Dedicated Management Team (2/2) Jignesh Desai Gautam Shah Jatin Gajjar President - Finance President - US Operations Chief Technology Officer ▪ 30+ years of experience in finance and accounting ▪ 30+ years of experience in pharmaceutical ▪ 30+ years of experience in pharmaceutical
Slide 30: Strong R&D Capabilities Driving Differentiated Product Portfolio
Strong R&D Capabilities Driving Differentiated Product Portfolio R&D Site 1 - USA R&D Site 1 - USA Oral Oral ▪ Internal research ORS Injectables API ▪ In-House R&D in US for Solids Liquids ▪ Information available Controlled Substances on subscribed databases R&D Site 2 - India ▪ Helps in dossier pre
Slide 31: Accredited Manufacturing Facilities (1/2)
5 Accredited Manufacturing Facilities (1/2) Atlanta Facility Ahmedabad, Chhatral Facility 378,943 Sq. Ft. Total Area Facility 12 2 Manufacturing Lines Manufacturing Lines 185,300 Sq. Ft. 4 Total Area Dosage Forms General Oral Beta Lactum Strong Regulatory Track Record Dosage Injectables Orals USFDA
Slide 32: Accredited Manufacturing Facilities (2/2)
Accredited Manufacturing Facilities (2/2) Apnar Pharma Plant ✓ Manufacturing facility commenced in 2021 & USFDA Approval received in September 2022 ✓ 2 land parcel available of total land area of ~49,250 Sq. Mts. Facility constructed on 1 plot (~4,500 Sq. Mts) with construction of ~40,000 Sq. Ft. La
Slide 33: Industry Overview
Industry Overview Private & Confidential
Slide 34: Global Pharma Market
Global Pharma Market Global pharma market is expected to grow at …regulated market will continue to dominate the US continues to exert influence on Global pharma market 6.6% from 2023-28… global pharma market Global pharma market by product type (USD bn) Global pharma market by region (USD bn) Share
Slide 35: Regulated Pharma Market
Regulated Pharma Market Regulated markets to dominate the global pharmaceutical sector, driven by their access to a growing innovative drug market & a thriving generics market Regulated markets constitute 77% of the global North America accounts for 62% of regulated New generics and patent expiratio
Slide 36: Emerging Pharma Market
Emerging Pharma Market Emerging pharma market Overview of India pharma market Emerging markets to outpace developed ones… IPM is amongst the fastest growing in the Oral solids will dominate IPM world… Emerging pharma market size (USD bn) Indian pharma market size (USD bn) Indian pharma market by dos
Slide 37: Senores Pharmaceuticals Limited – Contact Us
SENORES PHARMACEUTICALS LIMITED CONTACT US Senores Pharmaceuticals Limited Strategic Growth Advisors Private Limited CIN: L24290GJ2017PLC100263 CIN: U74140MH2010PTC204285 Mr. Deval Shah – Whole Time Director & CFO Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98